Stem Cell Clinic

The global transplant diagnostics market is expected to grow at a CAGR of over 6% during the forecast period 2019-2025 – Yahoo Finance

NEW YORK, Feb. 14, 2020 /PRNewswire/ --

The global transplant diagnostics market is expected to grow at a CAGR of over 6% during the forecast period 20192025.

Read the full report: https://www.reportlinker.com/p05862336/?utm_source=PRN

The following factors are likely to contribute to the growth of the transplant diagnostics market during the forecast period: Growing Number of Transplantations & Prevalence of Chronic Diseases Increasing Shift from Serological to Molecular Diagnostic Testing in Transplant Patients Emergence of cfDNA in Transplant Diagnostics Increasing Focus on Identifying New Biomarkers for Minimizing Transplantation Rejection

The global transplant diagnostics market is growing at a steady rate, which is expected to continue during the forecast period. The high demand for molecular diagnostic tests and the availability of technologically advanced devices with favorable patient demographics are mainly contributing to the high demand for transplant diagnostics devices. Ongoing technological advancements and innovations witnessed in the development of new genomic, transcriptomic, and proteomic biomarkers, especially in the molecular segment, can provide personalized management for transplantation and can detect rejection episodes and infections early, thereby improving the patient outcomes and success rate.

The study considers the present scenario of the global transplant diagnostics market and its market dynamics for the period 2019?2025. It covers a detailed overview of several market growth enablers, restraints, and trends. The study offers both the demand and supply aspects of the market. It profiles and examines leading companies and other prominent companies operating in the market.

Transplant Diagnostics Market: Segmentation

This research report includes detailed market segmentation by product, application, technology, transplantation type, end-user, and geography. The increasing usage of a wide array of reagents and test kits to perform transplant diagnostics tests is a significant factor affecting the growth of the reagents & consumables product segment. The segment is growing at a faster rate than the instruments & software product segment due to their recurring purchase by end-users for performing molecular and non-molecular transplant tests. The growth in technological advancements such as NGS and PCR-based molecular testing techniques is another factor driving the adoption of molecular transplant assays, test kits, and reagents.

The instruments and software segment is growing due to the rise in organ and tissue transplantations and the adoption of advanced techniques. The segment is growing at a relatively slow pace than the consumables & test kits segment as it is capital intensive, and purchasing decisions for these equipment depend on financial resources and budget allocations. However, the recent trends in automation and integration of several medical platforms have led to the introduction of innovative transplant diagnostic analyzers, thereby driving the growth of the segment.

The research application segment is likely to witness faster growth than the clinical application segment as the number of research activities and clinical trials related to transplantation, especially stem cells, is increasing worldwide. The increase in the number of clinical trials and ongoing research activities to improve clinical outcomes is encouraging end-users to effectively screen donors and recipients, perform compatibility assessments and diagnose complications such as organ rejection and infections using molecular and non-molecular tests.The diagnostics applications segment is growing at a healthy rate and is expected to grow during the forecast period. Transplantation is the treatment of choice for several patients with end-stage organ failure diseases. Significant signs of progress have been achieved both in short-term outcomes and long-term graft survival due to the increasing availability of molecular and serological-based tests to monitor transplant patients. Hence, technological improvements have further increased the application of the segment.

The growing number of solid organ and stem cell replacement, advances in organ transplantation, increase in funding and research grants, and improved public-private investments, and the shift from serological-based tests to gene-based HLA profiling are major factors contributing the growth of the segment. The growing adoption of molecular-based techniques in transplantations with the wide availability of PCR and sequence-based products is contributing to the growth of the segment.Advances in serology and cellular assays have broadened the scope of transplant immunology technologies. Non-molecular tests have also been contributing sizeable revenues to the global transplant diagnostics market. Their potential in antibody-based histocompatibility tests, especially for lymphocyte micro cytotoxicity testing, has been fueling the demand. Several vendors are offering non-molecular testing products, which is further contributing to the growth.

Solid-organ transplantation has become vital in treating patients suffering from terminal illnesses. Therefore, the global number of solid organ transplantations is increasing at a healthy rate despite interruptions in the organ donation supply mechanism. Incidences of end-stage organ failures are high among patients with chronic diseases, thereby increasing the need for solid organ transplantations. The growth in hematological cancer cases is a key factor for the increasing demand for stem cell therapy worldwide.

Standard reference laboratories conduct tests to identify donor receiver compatibility pre-transplantation. As the number of organs, cells, and tissue replacements is growing worldwide, the demand for laboratory testing is likely to rise at a steady rate. Government financial support for these laboratories is another major factor for the growth of the segment. Academic institutes & research laboratories end-users are growing at a healthy rate as these centers conduct research studies for evaluating the efficacy and safety of immunosuppressive therapies for organs, cell, and tissue replacements.Healthcare professionals in hospitals and transplant centers use various instruments, accessories, and software for conducting pre and post-transplantation diagnostics tests. The market is growing at a healthy rate due to the adoption of advanced instruments accessories and software for organs, cells, and tissue transplantations. The availability of skilled healthcare professionals to perform diagnostics tests also attracts more patients to hospitals and transplant centers. Also, favorable reimbursement for transplant diagnostics is another factor boosting the end-user segment.

Market Segmentation by Product Instruments & Software Consumables & Test KitsMarket Segmentation by End-user Standards Reference Laboratories Hospitals and Transplant Centers Research and Academic CentersMarket Segmentation by Transplant Type Solid Organs Soft TissuesMarket Segmentation by Technology Molecular Non-molecularMarket Segmentation by Application Diagnostic Research

Insights by Geography

The presence of a large pool of the patient population with terminal diseases and the high acceptance of advanced and innovative molecular procedures for transplant diagnostics have collectively supported the growth. France, the UK, Spain, Germany, and Italy are the major revenue contributors to the Europe market. The availability of highly sophisticated healthcare infrastructure and high awareness of advanced transplant procedures are contributing to the growth during the forecast period.The APAC region has the largest population density and the highest proportion of various chronic diseases. China is the major revenue contributor in APAC. The region is expected to witness significant growth due to advancements in healthcare infrastructure, the rise in healthcare expenditure, and favorable public and private initiatives.

Market Segmentation by Geography Europeo Spaino Franceo Germanyo UKo Italy North Americao Canadao US APACo Chinao Japano South Koreao Indiao Australia Latin Americao Brazilo Argentinao Mexico MEAo Saudi Arabiao Irano South Africao Israel

Insights by VendorsThe global transplant diagnostics market is moderately competitive and characterized by the presence of a few players offering these products. It is consolidated with a few players accounting for around 75% of the overall market in 2019. The market is witnessing rapid technological advancements, especially in the molecular diagnostics segment. Moreover, key players are witnessing increased competition from various regional and local players globally.

Key Vendors Thermo Fisher Scientific Hoffmann-La Roche bioMrieux Bio-Rad Laboratories QIAGEN Immucor

Other Vendors BAG Diagnostics CareDx ELITechGroup Genome Diagnostics Illumina NanoString Technologies Omixon Transplant Genomics Wakunaga Pharmaceutical

Key Market InsightsThe analysis of the transplant diagnostics market provides sizing and growth opportunities for the forecast period 20192024. Offers sizing and growth prospects of the transplant diagnostics market for the forecast period 20192024. Provides comprehensive insights on the latest industry trends, forecast, and growth drivers in the market. Includes a detailed analysis of growth drivers, challenges, and investment opportunities. Delivers a complete overview of segments and the regional outlook of the transplant diagnostics market. Offers an exhaustive summary of the vendor landscape, competitive analysis, and key strategies to gain a competitive advantage.

Read the full report: https://www.reportlinker.com/p05862336/?utm_source=PRN

About Reportlinker ReportLinker is an award-winning market research solution. Reportlinker finds and organizes the latest industry data so you get all the market research you need - instantly, in one place.

__________________________ Contact Clare: clare@reportlinker.com US: (339)-368-6001 Intl: +1 339-368-6001

View original content:http://www.prnewswire.com/news-releases/the-global-transplant-diagnostics-market-is-expected-to-grow-at-a-cagr-of-over-6-during-the-forecast-period-20192025-301005141.html

SOURCE Reportlinker

Follow this link:
The global transplant diagnostics market is expected to grow at a CAGR of over 6% during the forecast period 2019-2025 - Yahoo Finance

Stem Cell Therapy Market 2019 Analysis by Key Players, Share, Trend, Segmentation and Forecast to 2026 – Instant Tech News

Verified Market Research recently added a research report titled, Stem Cell Therapy Market Size and Forecast to 2026. The research report represents the potential growth opportunities that prevail within the global market. The report is analyzed on the idea of secondary research methodologies acquired from historic and forecast data. The Stem Cell Therapy market is expected to grow substantially and thrive in terms of volume and value during the forecast period. The report will provide an insight into the growth opportunities and restraints that construct the market. Readers can gain meaningful comprehension about the future of the market.

Global Stem Cell TherapyMarketwas valued at USD 86.62 million in 2016 and is projected to reach USD 221.03million by 2025, growing at a CAGR of 10.97% from 2017 to 2025.

Request a Sample of this report @ https://www.verifiedmarketresearch.com/download-sample/?rid=24113&utm_source=OMR&utm_medium=001

Top 10 Companies in the Stem Cell Therapy Market Research Report:

Osiris Therapeutics, Medipost Co., Anterogen Co., Pharmicell Co., HolostemTerapieAvanzateSrl, JCR Pharmaceuticals Co., Nuvasive, RTI Surgical, Allosource

Competitive Landscape

The insightful research report on the Stem Cell Therapy market includes Porters five forces analysis and SWOT analysis to understand the factors impacting consumer and supplier behavior. It helps the reader understand the strategies and collaborations that players are that specialize in combat competition within the market. The comprehensive report provides a big microscopic check out the market. The reader can identify the footprints of the manufacturers by knowing about the worldwide revenue of manufacturers, the worldwide price of manufacturers, and production by manufacturers during the forecast period of 2015 to 2019.

Global Stem Cell Therapy Market: Drivers and Restraints

The report offers underlying drivers that compel the consumers to take a position within the products and services. The detailed information assists readers in understanding the requirements of consumer demands. The report provides drivers at the local and global levels to assist determine the economic process . This information will help readers decide potential strategies that can help them stay ahead in the competitive industry.

Restraints provided in this section of the report contrasts the drivers segment as it explains the factors that can hamper the growth of the Stem Cell Therapy market during the forecast period. Restraints play a pivotal role in the global and regional market as it bends the prospective opportunities in the market. Readers can weigh and asses the drivers and restraints before making any investments or strategies.

Global Stem Cell Therapy Market: Segment Analysis

The report includes major segments like product type and end-user that provide an array of components that determine the portfolio of the Stem Cell Therapy industry. Each type furnishes information regarding the sales value during the forecast period. The understanding of the segment directs the readers in recognizing the importance of things that shape the market growth.

Global Stem Cell Therapy Market: Regional Analysis

This section of the report provides detailed information about each region and how numerous factors of that particular region affect the growth of the Stem Cell Therapy market. The government policies, weather, politics, and other factors determine the longer term of the market differently in each region. The major regions covered in the report include North America, Europe, Asia Pacific, the Middle East, and Africa, and others.

Ask for Discount @ https://www.verifiedmarketresearch.com/ask-for-discount/?rid=24113&utm_source=OMR&utm_medium=001

Table of Content

1 Introduction of Stem Cell Therapy Market

1.1 Overview of the Market1.2 Scope of Report1.3 Assumptions

2 Executive Summary

3 Research Methodology of Verified Market Research

3.1 Data Mining3.2 Validation3.3 Primary Interviews3.4 List of Data Sources

4 Stem Cell Therapy Market Outlook

4.1 Overview4.2 Market Dynamics4.2.1 Drivers4.2.2 Restraints4.2.3 Opportunities4.3 Porters Five Force Model4.4 Value Chain Analysis

5 Stem Cell Therapy Market, By Deployment Model

5.1 Overview

6 Stem Cell Therapy Market, By Solution

6.1 Overview

7 Stem Cell Therapy Market, By Vertical

7.1 Overview

8 Stem Cell Therapy Market, By Geography

8.1 Overview8.2 North America8.2.1 U.S.8.2.2 Canada8.2.3 Mexico8.3 Europe8.3.1 Germany8.3.2 U.K.8.3.3 France8.3.4 Rest of Europe8.4 Asia Pacific8.4.1 China8.4.2 Japan8.4.3 India8.4.4 Rest of Asia Pacific8.5 Rest of the World8.5.1 Latin America8.5.2 Middle East

9 Stem Cell Therapy Market Competitive Landscape

9.1 Overview9.2 Company Market Ranking9.3 Key Development Strategies

10 Company Profiles

10.1.1 Overview10.1.2 Financial Performance10.1.3 Product Outlook10.1.4 Key Developments

11 Appendix

11.1 Related Research

Get a Complete Market Report in your Inbox within 24 hours @ https://www.verifiedmarketresearch.com/product/Stem-Cell-Therapy-Market/?utm_source=OMR&utm_medium=001

About Us:

Verified market research partners with clients to provide insight into strategic and growth analytics; data that help achieve business goals and targets. Our core values include trust, integrity, and authenticity for our clients.

Analysts with high expertise in data gathering and governance utilize industry techniques to collate and examine data at all stages. Our analysts are trained to combine modern data collection techniques, superior research methodology, subject expertise and years of collective experience to produce informative and accurate research reports.

Contact Us:

Mr. Edwyne FernandesCall: +1 (650) 781 4080Email: [emailprotected]

TAGS: Stem Cell Therapy Market Size, Stem Cell Therapy Market Growth, Stem Cell Therapy Market Forecast, Stem Cell Therapy Market Analysis, Stem Cell Therapy Market Trends, Stem Cell Therapy Market

Here is the original post:
Stem Cell Therapy Market 2019 Analysis by Key Players, Share, Trend, Segmentation and Forecast to 2026 - Instant Tech News

Study shows how a tiny and strange marine animal produces unlimited eggs and sperm over its lifetime – National Institutes of Health

News Release

Thursday, February 13, 2020

NIH-supported research of Hydractinia could provide clues to human reproductive conditions.

A little-known ocean-dwelling creature most commonly found growing on dead hermit crab shells may sound like an unlikely study subject for researchers, but this animal has a rare ability it can make eggs and sperm for the duration of its lifetime. This animal, called Hydractinia, does so because it produces germ cells, which are precursors to eggs and sperm, nonstop throughout its life. Studying this unique ability could provide insight into the development of human reproductive system and the formation of reproductive-based conditions and diseases in humans.

By sequencing and studying the genomes of simpler organisms that are easier to manipulate in the lab, we have been able to tease out important insights regarding the biology underlying germ cell fate determination knowledge that may ultimately help us better understand the processes underlying reproductive disorders in humans, Dr. Andy Baxevanis, director of the National Human Genome Research Institutes (NHGRI) Computational Genomics Unit and co-author of the paper. NHGRI is part of the National Institutes of Health.

In a study published in the journal Science, collaborators at NHGRI, the National University of Ireland, Galway, and the Whitney Laboratory for Marine Bioscience at the University of Florida, Augustine, reported that activation of the gene Tfap2 in adult stem cells in Hydractinia can turn those cells into germ cells in a cycle that can repeat endlessly.

In comparison, humans and most other mammals generate a specific number of germ cells only once in their lifetime. Therefore, for such species, eggs and sperm from the predetermined number of germ cells may be formed over a long period of time, but their amount is restricted. An international team of researchers have been studying Hydractinias genome to understand how it comes by this special reproductive ability.

Hydractinia lives in colonies and is closely related to jellyfish and corals. Although Hydractinia is dissimilar to humans physiologically, its genome contains a surprisingly large number of genes that are like human disease genes, making it a useful animal model for studying questions related to human biology and health.

Hydractinia colonies possess feeding polyps and sexual polyps as a part of their anatomy. The specialized sexual polyps produce eggs and sperm, making them functionally similar to gonads in species like humans.

During human embryonic development, a small pool of germ cells that will eventually become gametes is set aside, and all sperm or eggs that humans produce during their lives are the descendants of those original few germ cells. Loss of these germ cells for any reason results in sterility, as humans do not have the ability to replenish their original pool of germ cells.

In a separate study, Dr. Baxevanis at NHGRI and Dr. Christine Schnitzler at the Whitney Lab have completed the first-ever sequencing of the Hydractinia genome. In this study, researchers used this information to scrutinize the organisms genome for clues as to why there are such marked differences in reproductive capacity between one of our most distant animal relatives and ourselves.

Having this kind of high-quality, whole-genome sequence data in hand allowed us to quickly narrow down the search for the specific gene or genes that tell Hydractinias stem cells to become germ cells, said Dr. Baxevanis.

The researchers compared the behavior of genes in the feeding and sexual structures of Hydractinia. They found that the Tfap2 gene was much more active in the sexual polyps than in the feeding polyps in both males and females. This was a clue that the gene might be important in generating germ cells.

The scientists next confirmed that Tfap2 was indeed the switch that controls the process of perpetual germ cell production. The researchers used the CRISPR-Cas9 gene-editing technique to remove Tfap2 from Hydractinia and measured the resulting effects on germ cell production. They found that removing Tfap2 from Hydractinia stops germ cells from forming, bolstering the theory that Tfap2 controls the process.

The researchers also wanted to know if Tfap2 was influencing specific cells to turn into germ cells. Their analysis revealed that Tfap2 only causes adult stem cells in Hydractinia to turn into germ cells.

Interestingly, the Tfap2 gene also regulates germ cell production in humans, in addition to its involvement in myriad other processes. However, in humans, the germ cells are separated from non-germ cells early in development. Still, despite the vast evolutionary distance between Hydractinia and humans, both share a key gene that changes stem cells into germ cells.

This press release describes a basic research finding. Basic research increases our understanding of human behavior and biology, which is foundational to advancing new and better ways to prevent, diagnose and treat disease. Science is an unpredictable and incremental process each research advance builds on past discoveries, often in unexpected ways. Most clinical advances would not be possible without the knowledge of fundamental basic research.

The National Human Genome Research Institute (NHGRI) is one of the 27 institutes and centers at the NIH, an agency of the Department of Health and Human Services. The NHGRI Division of Intramural Research develops and implements technology to understand, diagnose and treat genomic and genetic diseases. Additional information about NHGRI can be found at: https://www.genome.gov.

About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIHTurning Discovery Into Health

###

Read this article:
Study shows how a tiny and strange marine animal produces unlimited eggs and sperm over its lifetime - National Institutes of Health

Flow Cytometry Market to be Worth Over $6.4 Billion by 2027 With CAGR of 8.2%| Top Key Players Like – PharmiWeb.com

Meticulous Research leading global market research company published a research report titledFlow Cytometry Market by Product & Solution (Consumables, Instrument, Software, Service), Technology (Cell-based, Bead-based), Application (Cancer, Immunology, Hematology), and End-user (Pharmaceutical, Biotech, Academia) Global Forecast to 2027.

According to this latest publication from Meticulous Research, the globalFlow Cytometry Market is expected to grow at a CAGR of 8.2% from 2019 to reach to $6.4 billion by 2027. The growth of the flow cytometry market is mainly attributed to the rising global incidence and prevalence of chronic diseases, increasing adoption of flow cytometry techniques in research and academia, and growing initiatives in the field of immunology and immuno-oncology researches. Moreover, the evolving pipeline for stem cell research and the adoption of recombinant DNA technology for antibody production offer significant growth opportunities for the players operating in this market. However, complexities related to reagents development is the key factor expected to hinder the adoption of flow cytometry products to a certain extent.

Access Free Complete Free Sample PDF Copy Here:https://www.meticulousresearch.com/request-sample-report/cp_id=5067

Key questions answered in the report-

Which are the high growth market segments in terms of product & services, technology, application, end-users, and region/countries?What was the historical market for flow cytometry across the globe?What are the market forecasts and estimates for the period 2019-2027?What are the major drivers, restraints, opportunities, and challenges in the overall flow cytometry market?Who are the major players in the flow cytometry market?How is the competitive landscape and who are the market leaders in the overall flow cytometry market?What are the recent developments in the overall flow cytometry market?What are the different strategies adopted by the major players in the overall flow cytometry market?What are the geographical trends and high growth regions/ countries?

Have Any Query? Ask Our Experts Here: https://www.meticulousresearch.com/speak-to-analyst/cp_id=5067

The global flow cytometry market study presents historical market data in terms of values (2017 and 2018), estimated current data (2019), and forecasts for 2027- by product & solution (consumables, instrument, software, service), technology (cell-based, bead-based), application (cancer, immunology, hematology, industrial), end-user (pharmaceutical & biotech companies, research & academia, diagnostic laboratory) forecast to 2027. The study also evaluates industry competitors and analyzes the market at a regional and country level.

Based on technology,the cell-based technology segment held the largest share of the overall flow cytometry market in 2019. The large share of this segment is mainly attributed to the increasing utilization of this technology in research and development activities of novel therapeutic drugs and the advantage of analyzing characteristics and properties of targeted cells with ease. On the other hand, bead-based technology is expected to grow at a higher CAGR during the forecast period owing to the several procedural advantages offered by this technology.

Based on product and solution,the consumables and reagents segment accounted for the largest share of the overall flow cytometry market in 2019 and is expected to grow at the highest CAGR during the forecast period. The commercialization of high-quality application-specific reagents and assays by end-users is supporting the growth of this segment. Also, the continuous requirement of flow cytometry reagents by end-users further supports the growth of this segment.

Based on the end-user,the flow cytometry market is broadly segmented into pharmaceutical & biotechnology companies, diagnostic laboratories, and research & academic institutes. During the forecast period, the diagnostic laboratory segment is expected to register the fastest growth in the flow cytometry market. Some of the major factors contributing to the fastest growth of this segment are rising prevalence of chronic and infectious diseases, growing awareness regarding various chronic diseases, rising willingness to get an accurate diagnosis, and a growing number of laboratories adopting flow cytometers as the advanced diagnostic technology.

Check complete table of contents with a list of table and figures:https://www.meticulousresearch.com/product/flow-cytometry-market-5067/

Geographically, North America commanded the largest share of the global flow cytometry market in 2019, followed by Europe and Asia Pacific. The factors such as the availability of skilled professionals, higher awareness level, and the presence of supportive government reforms for the development of advanced technologies are accelerating the flow cytometry market in the North American region.

Key players:

The key players operating in the global flow cytometry market are Agilent Technologies, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Apogee Flow Systems Ltd. (U.K.), Sysmex Partec GmbH (Germany), Luminex Corporation (U.S.), Miltenyi Biotec GmbH (Germany), Bio-Rad Laboratories, Inc. (U.S.), bioMrieux S.A. (France), Cytonome/ST LLC (U.S.), Beckman Coulter, Inc. (U.S.), and Becton, Dickinson and Company (U.S.) among others.

Download Sample Report Now !! https://www.meticulousresearch.com/download-sample-report/cp_id=5067

Related Reports:

Infectious Disease Diagnostics Market by Product (Assays and Kits, Instruments, and Software and Services), Technology (Immunodiagnostics, NGS, PCR), Disease Type (Hepatitis, HIV, HPV, Tuberculosis), End User, and Geography Global Forecast to 2025

In Vitro Diagnostics Market | IVD Market By Product (Reagent, Instruments, Software, Service), Technique [Immunoassay, Clinical Chemistry (Lipids, Renal, Thyroid), PCR], Application (Hematology, Diabetes, Nephrology, Oncology), End User (Hospital, POC) Global Forecast to 2024

Contact Us:

Meticulous Research

Email-sales@meticulousresearch.com

Contact Sales- +1-646-781-8004

Connect with us on LinkedIn-https://www.linkedin.com/company/meticulous-research

This content has been distributed via WiredRelease press release distribution service. For press release service enquiry, please reach us at contact@wiredrelease.com.

See original here:
Flow Cytometry Market to be Worth Over $6.4 Billion by 2027 With CAGR of 8.2%| Top Key Players Like - PharmiWeb.com

Global Cord Blood Stem Cell Market Newest Research Report In PDF With Forecast [2020-2029] : Cord Blood Registry Systems Inc, Viacord Inc., China Cord…

The new research report providing thorough analysis on GlobalCord Blood Stem Cell Marketwhich peaks the market size, inclusive market dynamics and high technology updates of Cord Blood Stem Cell market with respect to industry opportunities, threats, challenges, constraints, cost structure and current trend in the market. The Cord Blood Stem Cell industry report is a thorough study of the market where the customer can gain key intuition into the market such as the performance of the market in terms of its market (size and value) for its various segmentations such as storage service, application, and region. This research assists to understand the competitive outlook of Cord Blood Stem Cell market by key players Cord Blood Registry Systems Inc, Viacord Inc., China Cord Blood Corporation., Cord Blood America Inc, Cryo-Cell International Inc, Cryo-Save AG., Cordlife Group Ltd., Vita 34 AG., Lifecell International Pvt. Ltd., Stemcyte Inc..

The research report consists of primary and secondary data which has been further epitomized through various charts, bar graphs, pie charts, tables and market figures. Additionally, detailed landscaping, Cord Blood Stem Cell economic strategy, marketing scheme, as well as SWOT analysis & Porte Five Forces Analysis of the market players have been provided in the Cord Blood Stem Cell report. It also includes the inventive trends, executing a rational pricing stats in the competitive Cord Blood Stem Cell market. The report also categorizes the market in terms of volume and revenue [Million USD].

To Obtain All-Inclusive Information On Forecast Analysis Of GlobalCord Blood Stem CellMarket, Download FREE SamplePDF Report Herehttps://marketresearch.biz/report/cord-blood-stem-cells-market/request-sample

The Cord Blood Stem Cell market report covers revenue number, product details, and sales of the leading Cord Blood Stem Cell corporations. The international market for Cord Blood Stem Cell has been researched with every detail in the publication with increased prominence on various important factors such as opportunities, and self-controlled, growth drivers. Each of the factors that concern to creation of the Cord Blood Stem Cell market dynamics has been studied and analyzed in detail by the Cord Blood Stem Cell analysts, so as to offer the best and most assessing and comprehensive study to the buyers of Cord Blood Stem Cell report.

The snapshot or the directional summary that has been provided in the Cord Blood Stem Cell market intelligence study has been designed in such a way that it will give a quick overview of the market for receiving information on the go. This could assist Cord Blood Stem Cell readers with hands-on data required for decision making during their progress journey in the Cord Blood Stem Cell market.

Global Cord Blood Stem Cell Market Research Report 2020-2029 Includes

Download Free Sample PDF Copy of This Research Report Now!

Geographically, this Cord Blood Stem Cell report is divided into different key regions, with production, Cord Blood Stem Cell utilization, income (million USD), and market share and the rate of growth in these regions, from 2020 to 2029 (forecast), covering Cord Blood Stem Cell market in North America (U.S., Canada, Mexico), Europe (Germany, U.K., France, Italy, Russia, Spain, etc), South America (Brazil, Argentina, etc), Middle East & Africa Cord Blood Stem Cell market (Saudi Arabia, South Africa, etc) and its Share (%) and CAGR for the predicted period 2020 to 2029.

The Key Points of this Cord Blood Stem Cell Market Report are:

1) To survey and forecast the market size share of Cord Blood Stem Cell, in terms of value and volume.

2) Provide detailed information concerning the Cord Blood Stem Cell major factors (opportunities, drivers, restraints, and industry-specific challenges) influencing the growth of Cord Blood Stem Cell market.

3) To study the future outlook and prospects for the Cord Blood Stem Cell market with Marketing Price (Price and Margin, Factors of Price Change, Manufacturers Gross Margin Analysis)

4) To analyze the global key regions Cord Blood Stem Cell market potential and advantage, opportunity and challenge, restraints and risks.

5) Detail Profile of the dominant players and Cord Blood Stem Cell comprehensively analyses their market status in terms of ranking and core capability along with in-depth the Cord Blood Stem Cell competitive landscape for the market leaders.

6) Study competitive developments like partnerships and joint ventures, Cord Blood Stem Cell new product developments, expansions and research and development of Cord Blood Stem Cell market.

Inquire/Speak To Expert for Further Detailed Information About Cord Blood Stem Cell Report:https://marketresearch.biz/report/cord-blood-stem-cells-market/#inquiry

Note: The historical years of the report and the forecast period can be personalized upon request. [Post Your Research Requirements] In addition, the scope of the published report can be changed as needed, detailed geography or country-based information can be given as part of the customization process.

About Us:

MarketResearch.Biz is a specialized market research, analytics, and solutions company, offering strategic and tactical support to clients for making well-informed business decisions. We are a team of dedicated and impassioned individuals, who believe strongly in giving our very best to what we do and we never back down from any challenge. The company offers services such as data mining, information management, and revenue enhancement solutions and suggestions. We cater to industries, individuals, and organizations across the globe, and deliver our offerings in the shortest possible turnaround time.

Contact Us:

Mr. Benni Johnson (inquiry@marketresearch.biz)

MarketResearch.Biz (Powered By Prudour Pvt. Ltd.)

420 Lexington Avenue, Suite 300

New York City, NY 10170,

United States

Website:https://marketresearch.biz

See the rest here:
Global Cord Blood Stem Cell Market Newest Research Report In PDF With Forecast [2020-2029] : Cord Blood Registry Systems Inc, Viacord Inc., China Cord...

State of the Science for Multiple Myeloma: Change in the Right Direction – Cancer Network

In a workshop held by the FDA in partnership with the American Association for Cancer Research (AACR) on February 13, 2019 in Wardman Park, Washington D.C., researchers from various institutions discussed the current state of African American outcomes and treatment in multiple myeloma trials and the clinical implications.

Although theres still this disparity, the rate of change in the right direction seems to be similar [for Caucasian and African American populations], Kenneth C. Anderson, MD, FAACR, program director for the Jerome Lipper Multiple Myeloma Center and LeBow Institute for Myeloma Therapeutics at the Dana-Farber Cancer Institute, said of the findings.

In an analysis based on preliminary FDA findings that suggested there was limited enrollment of African Americans in multiple myeloma clinical trials, researchers looked to see if there were differences in outcomes due to race and if there are differences in screen failure rates that contribute to differences in enrollment. Additionally, they looked to address if eligibility criteria are restrictive for certain demographic subgroups.

The presenters, Laura Fernandes, PhD, and Bindu Kanapuru, MD, of the FDA, summarized that enrollment of black patients was significantly less in their pooled dataset compared to white patients. Additionally, there were no conclusive differences in the different racial categories in regard to overall response rate, progression-free survival, and overall survival.

Moreover, more black patients failed to meet the screening criteria than their white and Asian study counterparts. In regard to the screen failure analysis, Kanapuru said, In general, fewer black patients were screened compared to whites and Asians. Second, among those who were screened for enrollment onto the multiple myeloma clinical trials, there is a trend towards higher screen failure rates for blacks compared to white.

Notably, Kanapuru indicated that the FDA has several ongoing initiatives and also published several guidances in an effort to expand eligibility criteria.

Moreover, in an evaluation of characteristics and outcomes of patients with multiple myeloma from an EHR-derived database, Kathleen Maignan, MSN, NP, from Flatiron Health, suggested that researchers were able to assess outcomes in patient subgroups that are likely to have lower representation or even be excluded from trials. Unadjusted results from the database indicated that black patients have similar or better outcomes when compared to white patients. However, adjusting for age and sex minimized this difference, especially for overall survival.

While real world data does have more African American patients, the representation still is not the same, Maignan said.

The research also suggested that black patients have a higher comorbidity burden, which could minimize their consideration for future trials. So, when we look at future directions, given the higher comorbidity burden amongst black patients, we see a potential to conduct future work in this subgroup which may have an unmet need, Maignan said. We also look forward to opportunities to further investigate genomic differences by race as we expand our clinical genomics database and availability there.

Furthermore, covering the scope of the issues, Nikhil C. Munshi, MD, of the Dana-Farber Cancer Institute, indicated that race has significant influence on outcomes and overall survival, as well as age within the different racial groups. Physiological and microenvironment parameters may also play a role with racial differences on outcomes in myeloma according to the researcher. Additionally, traditional prognostic factors may still have variability across racial differences.

So, the critical question now is to study the biological basis for these differences using genomics and all of the different technologies that are directly available to us, Munshi said. Moreover, he recommended that researchers studying patients with multiple myeloma evaluate the impact of race on therapeutic intervention and their PK/PD, as well as disease sensitivity compared to disease resistance.

Looking at biological and genomic differences of multiple myeloma, Shaji K. Kumar, MD, from the Mayo Clinic Cancer Center, Kumar indicated that MGUS is 2-3 times more common in African Americans, which correlates with the fact that myeloma is 2-3 times more common as well. Additionally, he found that there was a trend to earlier age of onset MGUS in blacks compare to whites, with the disparity in prevalence between blacks and whites being most striking within the 40-49 age group (3.26% [95% CI, 2.04-5.18] vs 0.53% [95% CI, 0.20-1.37];P= 0.0013).

I think we want to think about this differently, said Kumar. We are talking about a group of patients who get diagnosed about 10 years younger, who have better biology because of the fundamental underlying genetic differences, despite having advancements at diagnosis they tend to do better, so really the actual setting should be the African Americans should be doing a lot better than what theyre doing now.

The researcher then indicated that important role for screening in the African American patient population, especially with research showing that earlier screening would be beneficial in multiple myeloma. By treating them earlier, he presents the idea that their outcomes could actually be even better than the Caucasian patients. Additionally, Kumar indicated that the access to therapy, specifically stem cell therapy, needs to be addressed.

In the final presentation, Ajay K. Nooka, MD, from the Winship Cancer Institute of Emory University, discussed how to increase minority accrual in myeloma clinical trials through experiences and lessons learned within his own institution. At the system level, a lack of clinical trial infrastructure and insurance were the most prevalent barriers. At the individual level, a lack of trust, fear related to research participation, inadequate information about research, and access/convenience of participation all presented as barriers for clinical trial enrollment.

He listed some solutions that physicians within his institution brought attention to, including:

Following the presentation of the state of the science at the workshop, working groups presented recommendations for how to combat the addressed disparities in African American representation within multiple myeloma clinical trials.

Reference:

FDA-AACR Workshop to Examine Under-representation of African Americans in Multiple Myeloma Clinical Trials. Held Feb. 13, 2020. Wardman Park, Washington D.C.

View original post here:
State of the Science for Multiple Myeloma: Change in the Right Direction - Cancer Network

San Diego News Icon Don Bauder Gives His Heart to Ideal Candidate Bloomberg – Times of San Diego

Share This Article:Mike Bloomberg has a new fan in retired San Diego business journalist and columnist Don Bauder (inset). Photos by Chris Stone, Ellen BauderAt 83, San Diego journalism legend Don Bauder is guarding his health playing hermit at home (to avoid the flu) and venturing out only for doctor visits.

Support Times of San Diego's growthwith a small monthly contribution

Bauder, a Colorado resident since 2003, was forced by heart issues to retire in 2018 as a San Diego Reader columnist. But now he admits hell be questioned about his mental health.

Hes backing Mike Bloomberg for president.

Here I am finally making headway against the heart problems and now I am considered a candidate for the loony bin, Bauder said by email Wednesday.

If exercise and multiple trips to doctors and hospitals will repair my brain as they seem to have helped my heart, I feel I can thwart oncoming dementia, although I have never claimed that I am either stable or a genius as President Donald Trump has. I am at least stable enough to hope that my candidate will not choke on verbal borscht, as Trump does almost every day.

Bauder isnt wearing rose-colored glasses, though.

He concedes that the former New York City mayor once stated that if women wanted to be known for their intelligence, they would spend less time at Bloomingdales and more time at the library.

Bloomberg called the remark a Borscht Belt joke, Bauder said.

The former San Diego Union-Tribune financial editor also noted that Bloomberg once stated that 95% of murderers are male minorities, 15 to 25 who deserve to be pushed up against the wall.

Bauder adds: Democrats desperately need the votes of women, African-Americans and Latinos. New Yorkers have told me that those minorities will never forget, although Bloomberg has renounced his widely criticized stop-and-frisk policy that clearly discriminated against minorities while he was mayor of New York.

But it wasnt until former U-T colleague Logan Jenkins outed himself as a Bloomberg fan that Bauder also emerged from the closet at least locally.

Bauder wrote Times of San Diego:

As a former newspaper columnist and magazine writer, I agree wholeheartedly with Logan Jenkins. After a lot of pondering, I have concluded that Bloomberg is the ideal Democratic candidate. I started out backing Biden, but have become quite disenchanted. Unlike Trump, Bloomberg is a self-made billionaire.

Unlike Trump, who is clearly a sociopath on steroids, as well as a pathological liar and malignant psychotic narcissist, Bloomberg is eminently stable and also brilliant, as he proved in his business career and as mayor of New York City. I would add one thing to what Logan says: we desperately need a female on the ticket. As shown in 2018, females can see through Trump.

I would suggest Kamala Harris; her minority status would help balance the ticket. I worry that Bloombergs stop and frisk mistake will continue to turn off minorities.

Like Bloomberg, Bauder is a former Republican. (From 1960 to 1964, when he was in advertising and PR, Bauder voted for Richard Nixon.)

Since 2004, he says, hes voted for Democratic presidential candidates.

This year, however, I had problems, he wrote Wednesday. I feared that both Bernie Sanders and Elizabeth Warren had gone too far. I dont like Medicare for All. Those who want to keep their private plans should be able to do so. I cant see free higher education for all. Frankly, I think too many students are in college now.

Bauder calls student debt a cancerous problem, but cant see canceling it out.

Should we reimburse those who have already paid off their debt? I cant see giving stipends to families descended from slaves, he said. If anybody deserves to be paid off, its Native Americans, from whom we stole our country.

He said his cautious views left him with moderate choices.

I originally favored Joe Biden, but became disenchanted quickly. I liked Amy Klobuchar from the beginning, and I am happy to see her rising fast, he said. Pete Buttigieg is quite intelligent but needs seasoning. Ditto Tom Steyer.

Bauder considers the 2020 election critical.

Four more years of Trump would be disastrous, he said. Yes, I am concerned about more Russian hacking. Given the close 2016 races in Wisconsin, Michigan and Pennsylvania, we should all worry about Russian hacking this year.

Climate change is the most critical issue for Bauder because if the world doesnt do more to curb greenhouse gases, the world as we know it may suffocate by the end of the century.

This interview was conducted via email.

Times of San Diego: What does Mike Bloomberg offer?

Don Bauder: First: money. Lots of it. Hes worth close to $60 billion, making him 14th-richest in the world, according to Forbes. Unlike Trump, Bloomberg made the money himself. And he is ACTUALLY worth that.

Trump may not even be a billionaire, despite his claims to be worth $10 billion. The biggest advantage of Bloombergs wealth is that he can flood the nation with ads showing that Trump is a phony. Indeed, Bloomberg is already doing that, but you aint seen nuthin yet.

The Democratic Party is hurting for money. Bloomberg is NEEDED. He has not alienated the business community. Right now, money is flowing to Republican coffers because big business particularly pharmaceuticals, insurance, oil and the like is terrified of Sanders and Warren. That river of cash will slow down if the leftists are out of the picture.

As he has proved as New York mayor, Bloomberg is socially liberal and progressive. He supports abortion rights, government-funded stem cell research, same-sex marriage, gun control, environmentalism and routes to citizenship for illegal immigrants.

He is strong on public welfare and is a national leader in the battle against climate change. He wants to enhance the earned income tax credit. But unlike the other candidates, he has support from many in the business community. He is in favor of free trade. He is a fiscal conservative. He balanced New York Citys budget. Facing a crisis, he talked a Republican state Senate into passing a tax increase rather than slashing jobs.

He opposes wealth inequality proposing, for example, that his own taxes should go up. He says generally that taxes for the rich should rise. He would raise corporate taxes from 21% to 28% percent not enough in my judgment, but a good start.

He dislikes the fact that taxes on stock and bond gains are lower than income taxes. He would enhance worker rights and benefits although he has never been considered pro-union. He wants a $15 an hour minimum wage. He favors government-financed welfare projects. He believes rural communities should be more closely connected with urban centers.

During his political career, he has been a Republican, an independent and a Democrat. He knows his way around politics, having been mayor of New York City from 2002 to 2013.

He cracked one time that a short Jew would never be elected president, but I question that. He will absolutely eat up Trump in a debate. It will be obvious that he is 10 times smarter than Trump.

(Bauder cites the same metric in the San Diego mayors race, saying he favors Barbara Bry because of her intelligence.)

Your journalism career is marked by major investigations into scam artists and political boondoggles. What gives you confidence that Bloomberg has genuine concern for the common good and not himself and his affluent cohort?

He favors corporate welfare corporate projects partly funded by government. I consider most such projects to be scams, although few others do. As mayor of New York, he has warned the citizenry of scam artists on the loose. But early in his mayoral term he vetoed a bill against predatory lending.

Why should Sen. Kamala Harris be Bloombergs running mate?

First, the Democrats must have a female on the ticket on the top of the ticket or the vice president. If Bloomberg is at the top, a female must run for the second slot. A minority female would be greatly preferred. Kamala Harris fills that bill. Stacey Abrams or Oprah Winfrey (who says she doesnt want it) would also be excellent.

If Bloomberg doesnt break out in Super Tuesday voting, will he have a shot at winning enough delegates to prevail at Milwaukee Democratic National Convention?

If Bloomberg does poorly, he will have to consider dropping out. If he does drop out, he should continue giving his planned donations to the Democratic Party. Ditto Tom Steyer. Both must continue to give if they are no longer candidates. The Democratic Party is not in good financial shape. If Bloomberg loses, I would hope Sherrod Brown, senator of Ohio, would get in the race.

Bloomberg has credibility from his mayor terms and gun-control and climate-change work. But he was elected in a very liberal environment. Could he challenge Trump in red states?

You make a good point that Bloomberg might not go over well in red states where uneducated voters are abundant. Many Americans hate New Yorkers unfortunately, often for good reasons. But although Bloomberg is short in stature, many voters will realize that he would be the real alpha male in the race. He is tough and knowledgeable. He would take hard stands on many issues.

Handicap a Trump vs. Sanders contest.

Trump has already called Sanders a communist not a socialist, which he is. So we would have a rerun of Joe McCarthy. If Trump continues to call Sanders a communist, Democrats should call Trump and his ilk fascists. Down and dirty. I think Sanders would take the West Coast and most of the East Coast, including Florida.

But Trump would take states where education levels are low the South, and Northern states such as Montana, Wyoming, Idaho, North and South Dakota, Kansas, Nebraska and other traditionally red (redneck?) states. Colorado, New Mexico and even possibly Arizona could go for Sanders.

Ohio, Indiana and Iowa could go red and Wisconsin and Minnesota might go blue. Illinois could stay blue. Much depends on whether Americans realize that Trump is a pathological liar, sociopath, malignant psychotic narcissist. He seems totally out of control now.

Critics like Paul Heideman call Bloomberg a classic oligarch using his wealth to tilt the economic and political playing field in his favor. Can voters trust someone who uses vast wealth to gain support? How is billionaire Bloomberg better suited to the Oval Office than billionaire Steyer (or anyone else)?

Paul Heideman has a point. You are correct that some voters will see how many ads he spreads around and hold his wealth against him. But these people could be swayed by the wave of advertising.

What Bloomberg can do is massively sponsor ads that emphasize that Trump is a liar showing him saying one thing one day and the opposite the next day. Also, such ads could show that Trumps claims about the economy on his watch are false.

For example, Trump keeps repeating that the economy has done better under him than at other times. This is laughably false. GDP is growing a little over 2% now and there have been many times when it grew 3% and even 4%. Trump says unemployment is the lowest ever, and that is also false. These ads can also show Trump at his most vulgar. That might even go over well in redneck territory, however. Trumps racism through his dog whistles could be emphasized in certain markets but not in redneck areas.

Would Bloomberg address wealth inequality?

Bloomberg is strongly opposed to wealth inequality and says his own taxes should go up. However, he would only raise the corporate tax rate to 28% from 21%. Thats not enough, in my judgment. He believes income taxes for the rich should be boosted. He is also disgusted that taxes on stock and bond profits are lower than taxes on incomes.

He complains that economic growth is concentrated in a small number of regions. He would enhance worker rights and benefits although he has never been known as pro-union a possible negative. He wants a $15 minimum wage. He favors government-financed welfare projects. He would like to see rural communities better connected to urban growth centers. He wants to see research and development in regions needing development.

How is your health?

I saw my cardiologist just two weeks ago. I asked him if I was a candidate for a stent in my two arteries that are only moderately good. He said no. (Background: I have had two quadruple-bypass surgeries. The last one was in 1990. On average, the grafts last 30 years.) But cardiologists (I have had several) say this does not mean I have only two years to go.

The heart itself seems to be OK, but the concern is arteries or grafts from previous surgeries filling up. I will be 84 in May. I dont expect to make it to 90, but with lots of luck I may get half or a third of the way there.

San Diego News Icon Don Bauder Gives His Heart to Ideal Candidate Bloomberg was last modified: February 14th, 2020 by Ken Stone

>> Subscribe to Times of San Diegos free daily email newsletter! Click here

Read this article:
San Diego News Icon Don Bauder Gives His Heart to Ideal Candidate Bloomberg - Times of San Diego